Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Recruiting
- Zhejiang Cancer Hospital
-
Principal Investigator:
- Yuan Zhu, PhD
-
Contact:
- Jialin Luo, MD
- Phone Number: 0086-571-88122062
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Age:18-75 years
- Histologically confirmed locally advanced colorectal cancer (adenocarcinoma)
- The lower edge of the tumors located below 12 cm from the anal verge
- Karnofsky Performance Scale ≥70 points, Life expectancy ≥ 6 months
- No prior chemotherapy was used
- No history of regional radiation treatment inthe pelvic cavity
- Adequate hematologic function: Hb ≥ 100 g/L , WBC≥3.5×109, ANC ≥ 1.5×109 /L,PLT ≥ 100×109 /L Adequate renal function: Cr ≤ 1.5×ULN, TB≤2.5 × ULN Adequate hepatic function: ALT/AST ≤ 2.5×ULN, Alkaline phosphatase ≤ 2.5×ULN
- Patients without peripheral neuropathy
Exclusion Criteria:
- Other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ
- Rectal cancer patients with concurrent colon cancer
- Pregnant or lactating women
- Fertile female patients without using any contraceptives
- Allergic to cisplatin and fluorouracil
- Patients with previous peripheral neuropathy
- Serious complications: myocardial infarction, heart failure (NYHA Classification>II grade),psychiatric history and severe diabetes
- Treatment with other anti-cancer therapy(including Chinese herbal medicine)
- Organ transplant patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nimotuzumab plus chemoradiotherapy
|
50.4Gy/28F/5.5w
400mg/w,0-5w
130mg/m2 d1
825mg/m2 bid d1-5/w,1-5w
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pathology complete remission rate
Time Frame: 1 year
|
Pathology complete remission rate is the primary outcome measure.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
local recurrence rate
Time Frame: 5 years
|
5 years
|
|
overall survival
Time Frame: 5 years
|
5 years
|
|
Incidence of Adverse Events
Time Frame: up to 1 month after the last cycle
|
up to 1 month after the last cycle
|
|
tumor regression rate
Time Frame: 1 year
|
1 year
|
|
sphincter preservation rate
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Rectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Capecitabine
- Oxaliplatin
- Nimotuzumab
Other Study ID Numbers
Other Study ID Numbers
- ZhejiangCH-ARO2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.